"As at the date of this annual report the FDA has reviewed the IND submission and has one remaining question of the 6 that it initially raised in response to the Company’s IND submission. Paradigm will respond to the FDA by the end of August 2021 and intends to commence the global pivotal trial before the end of CY21."
Great update!
Ann: 2021 Annual Report and Appendix 4E, page-2
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
28.0¢ |
Change
0.010(3.70%) |
Mkt cap ! $97.94M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 29.0¢ | 27.5¢ | $189.1K | 668.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 65071 | 27.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.0¢ | 16299 | 1 |
View Market Depth
| Last trade - 16.10pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
28.0¢ |
Change
0.010 ( 0.11 %) |
||||
| Open | High | Low | Volume | ||
| 28.5¢ | 29.0¢ | 27.5¢ | 246669 | ||
| Last updated 15.59pm 10/05/2024 ? | |||||
| PAR (ASX) Chart |